Global Antiepileptic Drugs Market 2021 Industry Outlook, Comprehensive Insights, Growth and Forecast 2026

(MENAFN- The Express Wire) Global Antiepileptic Drugs Market 2021 Industry Outlook, Comprehensive Insights, Growth and Forecast 2026

Posted on Apr 16 2021 5:59 AM

"The Antiepileptic Drugs (AED) Market report provides an in-depth analysis of the market and focuses on aspects such as growth drivers, restraints, leading products, and major industry developments. It discusses the competitive landscape of the market and labels out leading players."

The global antiepileptic drugs market size is set to gain traction from the ever-increasing initiatives by manufacturers for producing novel and generic drugs for patients. Patents of numerous second generation drugs are on the verge of expiration. It is thus, opening door to new opportunities and upsurging competition amongst key players. It is likely to affect the market positively in the coming years. This information is provided by Fortune Business Insights™  in a recently published report, titled, ' Antiepileptic Drugs Market Size, Share & Industry Analysis, By Drug Generation (First Generation, Second Generation, and Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2019-2026 . The report further mentions that the AED market size stood at  USD 16.56 billion  in 2018 and is projected to reach  USD 20.33 billion  by 2026, exhibiting a CAGR of 2.4% during the forecast period.

The report covers:

• Global Antiepileptic Drugs Market trends, with detailed analysis on consumer trends & manufacturer trends.
• Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
• Key areas of investments identifying market opportunities and challenges in forecast timeframe.
• Competitive analysis of the industry players along with the overview on strategic management.
• Comprehensive company profiles of the major industry players.

Request a Sample Copy of the Research Report: 

Leading Players operating in the Antiepileptic Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Sanofi
• Pfizer Inc.
• GW Pharmaceuticals plc.
• UCB S.A.
• Eisai Co., Ltd.
• Sunovion Pharmaceuticals Inc.
• Lundbeck A/S
• GlaxoSmithKline plc.
• Other prominent players

Key questions answered in the report:

What will the market growth rate of Antiepileptic Drugs Market in 2026?

What are the key factors driving the global Antiepileptic Drugs Market?

Who are the key manufacturers in Antiepileptic Drugs Market space?

What are the market opportunities, market risk and market overview of the Antiepileptic Drugs Market?

What are sales, revenue, and price analysis of top manufacturers of Antiepileptic Drugs Market?

Who are the distributors, traders and dealers of Antiepileptic Drugs Market?

What are the Antiepileptic Drugs Market opportunities and threats faced by the vendors in the global Robotic Surgical Procedures industry?

What are sales, revenue, and price analysis by types and applications of Antiepileptic Drugs Market?

What are sales, revenue, and price analysis by regions of Robotic Surgical Procedures industry?

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Click here to get the short-term and long-term impact of COVID-19 on this Antiepileptic Drugs Market .

Please visit:

Drivers & Restraints-

Rising Government Funding on Development of New Drugs to Propel Growth

The incidence of epilepsy is high in the developing economies. As per a survey put forward by the World Health Organization (WHO) and the Epilepsy Foundation of America, in 2019, approximately 50 million populaces were living with the condition globally. Therefore, it is considered to be one of the most commonly occurring neurological disorders in worldwide. Out of these, around 80% of the masses resided in middle or low-income nations. Brazil, India, and China are the top three countries housing a large patient pool suffering from epilepsy.

Besides, three quarters of people living in low-income countries are devoid of medical treatment for epilepsy. Hence, the governments of many countries are taking initiatives to expedite the availability of better treatment options, as well as minimize the burden of this condition. The Morrison Government, for instance, invested USD 9.2 million in April 2019, to develop drugs for childhood epilepsy. However, shortage of such drugs across the globe may hinder the epilepsy drugs market growth during the forthcoming period.

Segment-

Second Generation Segment to Lead Stoked by Immense Popularity of Lyrica

In terms of drug generation, the market is grouped into first generation, second generation, and third generation. Out of these, the second generation segment is set to dominate the market. This includes prominent drugs, such as Banzel, Keppra, and Lyrica. Lyrica is one of the bestselling drugs provided by Pfizer Inc. and owns the maximum anticonvulsants drugs market share backed by its ability to control seizures and lower the impulses of the brain. However, its patient expired in 2019 and hence, other second generation drugs have been introduced in the market as they are also showcasing high potential in the treatment of epilepsy. The first generation segment held 31.5% market share in 2018. It is likely to experience slow growth because of reduction in sales.

Have Any Query? Ask Our Experts:

Detailed Table of Content:

Continued...

Report Focus:

• Extensive product offerings
• Customer research services
• Robust research methodology
• Comprehensive reports
• Latest technological developments
• Value chain analysis
• Potential Antiepileptic Drugs Market opportunities
• Growth dynamics
• Quality assurance
• Post-sales support
• Regular report updates

Reasons to Purchase this Report:

• Comprehensive analysis of the Antiepileptic Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
• Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
• Identifies market restraints and boosters.
• Identifies all the possible segments present in the market to aid organizations in strategic business planning.

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: [email protected]

Linkedin  | Twitter  | BLogs

MENAFN16042021004576010663ID1101926231

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.